Drugs / Trifluridine/Tipiracil Hydrochloride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05007132 | Dec 2021 → Dec 2029 expected | colorectal cancer | Dominik Paul Modest | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007132 ↗ |
| Route | Oral | “Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12” NCT05007132 ↗ |